CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today published research in Nature ...

ATP citrate lyase (ACL) knockdown (KD) causes tumor suppression and induces differentiation. We have previously reported that ACL KD reverses epithelial–mesenchymal transition (EMT) in lung cancer ...

Non-alcoholic fatty liver disease (NAFLD) affects over 25% of Canadians and is a leading risk factor for the development of type 2 diabetes, cardiovascular disease and liver transplant yet despite its ...

Esperion Therapeutics Inc. has described ATP citrate lyase (ACLY) inhibitors reported to be useful for the treatment of cancer, nonalcoholic or metabolic dysfunction-associated steatohepatitis ...

A research team has unraveled the three-dimensional structure and molecular mechanism of ATP citrate lyase (ACLY). This is a central metabolic enzyme -- a protein that accelerates chemical reactions - ...

The 3D structure of human ATP-citrate lyase, a metabolic enzyme that plays a key role in cancer cell proliferation and other processes. [Nimbus Therapeutics; Liang Tong, Columbia University, Nature] ...

Researchers from McMaster University and Espervita Therapeutics Inc. have identified the enzyme ATP citrate lyase (ACLY) as a key metabolic regulator of tumor-immune interactions in hepatocellular ...

The raw material for de novo fatty acid synthesis is acetyl-CoA, which can be obtained via the citrate shuttle pathway or from acetic acid. ACC and FASN catalyze the conversion of acetyl-CoA into ...